How did BTAI's revenue and expenses shift in Q4 2024?
5/8/2025 09:24pm
Bioxcel Therapeutics (BTAI) experienced a significant shift in its financials during Q4 2024, with total revenue reaching $366,000. However, the company did not report any expenses for the period, which is a notable aspect of its financial performance in this quarter.
|code|Ticker|Name|Date|Total Revenue|Total Expenses|market_code|
|---|---|---|---|---|---|---|
|BTAI|BTAI.O|Bioxcel Therapeutics|2024 Q1|582000||186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2024 Q2|1104000||186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2024 Q3|214000||186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2024 Q4|366000||186|